Done ADHD Telehealth: Pricing History, Trajectory, and What Patients Should Know

What Is Done and How Does Its Business Model Work?

Done operates as a subscription telehealth service that connects patients reporting ADHD symptoms with clinicians who can diagnose and prescribe Schedule II stimulant medications. The model is entirely cash-pay. No insurance is billed. Patients pay a recurring monthly fee to maintain access to a provider, and they fill prescriptions separately at a pharmacy.

The Subscription-Only Revenue Structure

The core tension in Done's model is that revenue comes from subscriptions, not outcomes. A patient who stays on a stimulant prescription indefinitely generates continuous monthly income for the platform. Critics, including researchers writing in JAMA Network Open, have flagged this structural incentive in cash-pay ADHD telehealth broadly. A 2023 analysis in JAMA Network Open found that telehealth platforms were associated with higher rates of new stimulant prescriptions compared with in-person care, raising questions about diagnostic rigor.

What the Fee Actually Covers

The monthly subscription at Done is described as covering provider consultations and care coordination. It does not cover the cost of the controlled substance itself. Adderall (mixed amphetamine salts) branded and generic, as well as methylphenidate products, require a separate pharmacy fill. Generic mixed amphetamine salts 20 mg range from roughly $30 to $90 per month at major pharmacies without a discount card, meaning a patient's true all-in monthly cost could exceed $250 to $290 at current Done pricing.

Done Pricing History: From Launch to 2025

Tracing Done's exact pricing is difficult because the company has not published an official price-change log. Reconstructing the trajectory requires cross-referencing archived web pages, Reddit threads (r/ADHD), BBB complaints, and consumer finance articles.

Early Pricing (2019-2021)

Done launched during a period when direct-to-consumer ADHD telehealth was essentially unregulated under pandemic-era DEA exemptions. The DEA's March 2020 COVID-19 telemedicine flexibilities allowed controlled-substance prescribing without an in-person evaluation, a policy that opened the market for platforms like Done, Cerebral, and Ahead. During this window, Done advertised rates in the $79 to $99 per month range, positioning itself as an affordable alternative to psychiatry waitlists that routinely ran 3 to 6 months.

Mid-Period Increases (2022-2023)

By 2022, Done had raised its base subscription to approximately $149 per month. The increase coincided with two market forces: broader awareness of ADHD telehealth (driving demand) and the beginning of federal scrutiny. The DEA's February 2023 proposed rule on telemedicine prescribing of controlled substances would have required an in-person evaluation before any Schedule II prescription. The proposed rule drew over 38,000 public comments and was subsequently modified, but the regulatory uncertainty appears to have coincided with Done tightening its intake criteria and raising prices.

Current Pricing (2024-2025)

Done's advertised fee reached approximately $199 per month by late 2024. At that rate, a patient paying for 12 months spends $2,388 per year on the subscription alone before a single pill is purchased. That figure exceeds what many traditional psychiatry practices charge for 4 to 6 annual follow-up visits when billed through insurance.

The table below provides a reconstructed price trajectory. Because Done has not published official pricing archives, these figures are approximations drawn from consumer complaint records and archived web content. Clinicians and patients should request current pricing directly from Done at the time of enrollment.

| Approximate Period | Reported Monthly Fee | Key Context | |---|---|---| | 2019-2020 | ~$79 | DEA pandemic flexibilities in effect | | 2021 | ~$99 | Rapid user growth phase | | 2022 | ~$149 | DEA proposed rules announced | | 2023 | ~$169-$179 | Congressional scrutiny of ADHD telehealth | | 2024-2025 | ~$199 | Ongoing DEA rule finalization |

Is Done Legit? Regulatory and Legal Context

"Is Done legit?" is the most common secondary search query on this topic. The answer is multi-part and depends on what "legit" means.

Corporate Registration and Licensure

Done is a registered U.S. Company. Its clinicians hold state medical licenses, and prescriptions are issued through licensed providers. In that narrow sense, Done is a legal operating entity, not a scam in the sense of taking money and delivering nothing.

DEA and Controlled-Substance Prescribing Rules

The harder legitimacy question concerns whether Done's prescribing practices meet federal standards. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires an in-person medical evaluation before a practitioner may prescribe a controlled substance via telemedicine. Pandemic-era exemptions suspended that requirement. As those exemptions expire and new DEA rules are finalized, platforms that built their entire model on no-in-person-required prescribing face genuine legal exposure.

The DEA has proposed special registration requirements for telemedicine providers prescribing Schedule II substances. If finalized with strict in-person requirements, Done's current clinical workflow may need significant restructuring.

Congressional Scrutiny

In 2022 and 2023, the Senate Finance Committee and the Senate Permanent Subcommittee on Investigations examined telehealth ADHD prescribing practices. While Done was not the sole target, the subcommittee's October 2022 report highlighted concerns about platforms approving stimulant prescriptions within minutes of intake. The FDA has not issued specific enforcement actions against Done as of this writing, but the FTC has been increasingly active in the direct-to-consumer health space.

Done Complaints: What BBB and Consumer Reports Show

Volume and Themes

The Better Business Bureau profile for Done shows over 200 complaints filed as of early 2025. The BBB is not a regulatory agency and complaint counts alone do not establish wrongdoing, but the themes across complaints are consistent enough to be informative.

The most frequent complaint categories include:

• Difficulty canceling subscriptions and continued billing after cancellation requests
• Prescription delays, sometimes exceeding 2 to 4 weeks, despite active subscriptions
• Abrupt provider changes with no notice, disrupting controlled-substance prescribing continuity
• Difficulty obtaining prior-authorization documentation for insurance reimbursement (since Done is cash-pay, this is sometimes sought retroactively)
• Customer service response times described as slow or unresponsive

Subscription-Cancellation Complaints in Detail

The cancellation complaints follow a recognizable pattern: a patient decides to leave Done, submits a cancellation request through the app or email, and then finds that billing continues for one or more additional months. In several BBB responses, Done stated that cancellations require a specific lead time (reportedly 30 days in some versions of its terms of service) and that charges incurred before cancellation is processed are non-refundable. Whether that policy is clearly disclosed at enrollment is disputed in multiple complaint threads.

What Done Says in Response

Done's BBB responses generally acknowledge the complaint, reference their terms of service, and offer partial credits in some cases. The company's BBB rating has fluctuated. These are not criminal findings; they represent a pattern of consumer experience worth factoring into any enrollment decision.

Clinical Context: ADHD Diagnosis Standards and What Telehealth Can Reasonably Deliver

What a Proper ADHD Evaluation Involves

The American Academy of Pediatrics (AAP) clinical practice guideline and adult ADHD guidance from the American Academy of Adult ADHD (now incorporated into broader psychiatric guidelines) describe a multi-step diagnostic process. For adults, this typically includes structured clinical interview covering symptom history back to childhood, validated rating scales such as the Conners' Adult ADHD Rating Scales (CAARS) or the Adult ADHD Self-Report Scale (ASRS-v1.1), review of prior records when available, and ruling out comorbid conditions including anxiety disorder, mood disorder, and sleep disorders that can mimic or exacerbate ADHD symptoms.

A 2024 JAMA Psychiatry editorial stated directly: "Brief asynchronous intake questionnaires are not equivalent to a structured clinical interview and may systematically overestimate ADHD prevalence in telehealth populations."

Whether Done's intake process meets this bar is unknown to us; the company does not publish its diagnostic protocol. Patients should ask any telehealth ADHD provider specifically what validated instruments their clinicians use and how symptom history is verified.

Stimulant Medications: What the Evidence Says

For confirmed ADHD, stimulant medications have a strong evidence base. A 2018 Lancet meta-analysis (N=10,068 adults across 133 trials) found that amphetamines produced the largest effect size for adult ADHD symptom reduction (standardized mean difference 0.79, 95% CI 0.64-0.93) compared with placebo. Methylphenidate showed an effect size of 0.49 (95% CI 0.36-0.61) in the same analysis.

These are real, meaningful treatment effects. The concern is not whether stimulants work. The concern is whether patients receiving them through rapid telehealth intake actually have ADHD.

Stimulant Shortages and Telehealth Prescribing Volume

The U.S. Has experienced ongoing shortages of mixed amphetamine salts since at least October 2022. The FDA's drug shortage database has listed amphetamine mixed salts extended-release products intermittently throughout 2023 and 2024. Some pharmacists and analysts have attributed part of this shortage to a surge in prescriptions driven by telehealth platforms, though this remains debated. The DEA's 2023 annual aggregate production quota for amphetamine was set at 42,750 kg, an increase from prior years, but supply chain issues persisted.

How Done Compares to Alternatives on Cost

Patients evaluating Done should compare all-in costs. Done is not the only option for cash-pay ADHD care, and it is not the cheapest.

Alternative Cost Structures

• Traditional psychiatry (in-person): Initial evaluation $300 to $600; follow-up visits $150 to $250, typically 4 per year, totaling $900 to $1,600 annually. Insurance often covers a substantial portion.
• Community mental health centers: Sliding-scale fees; sometimes as low as $0 to $50 per visit for qualifying patients.
• Other telehealth ADHD platforms (e.g., Cerebral, Talkiatry, Ahead): Pricing varies from $85 to $175 per month; some accept insurance for the psychiatric visit portion.
• Primary care physician: Many PCPs manage adult ADHD. An established patient with a prior diagnosis can often receive stimulant prescriptions from their PCP at the cost of a standard office visit, which is usually covered by insurance.

At $199 per month, Done is on the high end of the telehealth ADHD market. Patients without insurance who need diagnosis and treatment have options that cost meaningfully less.

Questions to Ask Before Enrolling in Any ADHD Telehealth Service

Before committing to a subscription-based ADHD telehealth platform, patients should get clear answers to the following:

1. What validated diagnostic instruments does the clinician use?
2. Is my assigned provider an MD, DO, NP, or PA, and what is their specialty training?
3. What is the cancellation policy, and is there a written confirmation process?
4. Will the platform provide documentation if I later want to seek insurance reimbursement or transition to an in-person provider?
5. What happens to my prescription if the platform changes its policies or loses its DEA registration?
6. Does the subscription fee change after the first month, and are price increases disclosed in advance?

Getting written answers to questions 3 and 6 before entering credit card information is a basic consumer-protection step worth taking.

The Regulatory Trajectory and What It Means for Done's Future

The DEA's final rule on telemedicine prescribing of Schedule II controlled substances was pending as of early 2025. The agency issued a temporary extension of pandemic flexibilities through the end of 2024 while working toward a permanent framework. Two scenarios are plausible.

If strict in-person requirements are imposed: Platforms like Done would need to either build hybrid care networks (with in-person evaluation partners) or exit the controlled-substance prescribing market. Neither transition is costless, and subscription prices would likely rise further or the business model could become non-viable.

If a telemedicine special registration pathway is established: Done could potentially qualify, but would face new compliance costs related to record-keeping, patient identity verification, and prescribing audits. Those costs would likely be passed to subscribers.

Either way, the $199-per-month trajectory is unlikely to reverse. Patients enrolled for ADHD management should have a contingency plan, specifically an identified in-person prescriber who could maintain their care if a platform-level disruption occurs.

Stimulant discontinuation without a plan can disrupt work performance, academic functioning, and daily life. Building in that backup is not pessimism. It is standard chronic-disease management.